Company profile
NEUMORA THERAPEUTICS, INC.
NASDAQ:NMRABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NAVACAPRANT | phase3 | — | 6 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04221230 | phase2 | completed | 2020-01-03 | 2022-04-08 | Neumora Therapeutics, Inc. | Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo |
| NCT06058013 | phase3 | completed | 2023-12-20 | 2026-05-06 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| NCT06058039 | phase3 | completed | 2023-12-21 | 2026-05-04 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| NCT06029439 | phase3 | terminated | 2023-11-10 | 2026-08-17 | Neumora Therapeutics, Inc. | Study to Assess the Safety and Effectiveness of NMRA-335140-501 |
| NCT06546995 | phase1 | completed | 2024-07-09 | 2025-11-19 | Neumora Therapeutics, Inc. | Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease |
FDA applications (0)
No records yet.